Welcome to our dedicated page for INSMED SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
Insmed Inc Chief Operating Officer Roger Adsett exercised options to acquire 88,060 shares of common stock at an exercise price of $14.56 per share. On the same date, he sold 88,060 shares in open-market transactions at weighted average prices of $163.18, $164.11, and $164.95 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025. Following these transactions, he directly holds 106,810 shares of Insmed common stock.
INSM Section 144 notice reports proposed sales of Common stock by Roger Adsett. The filing lists four sales dates and share counts: 02/03/2026: 791 shares; 01/08/2026: 2,059 shares; 01/07/2026: 802 shares; 01/06/2026: 1,429 shares. The entries appear under "Securities Sold During The Past 3 Months" and are labeled as Stock Plan Activity.
Insmed Incorporated is asking shareholders to vote at its virtual 2026 annual meeting on three items: electing two Class II directors, an advisory vote on 2025 executive pay, and ratifying Ernst & Young as auditor for 2026.
The company reports 2025 revenue of $606.4 million, driven by ARIKAYCE and the U.S. launch of BRINSUPRI, including a 19% year-over-year increase in global ARIKAYCE revenue and a stock price gain of over 150% in 2025. Insmed highlights a largely independent, skills-diverse Board, strong governance practices, and a pay program that is heavily equity-based and performance-linked, with about 94% of the CEO’s 2025 target direct compensation and 86% of other NEOs’ pay classified as “at risk.”
INSMED Inc Chief Legal Officer Michael Alexander Smith exercised stock options and sold shares in a pre-planned transaction. On March 30, 2026, he exercised options for 19,638 shares of common stock at exercise prices of $17.07 and $27.89 per share. The same day, he sold 19,638 shares of common stock at $150.98 per share under a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, he directly owned 51,871 shares of INSMED common stock.
INSM filing a Form 144 notice reporting proposed sales of Common Stock by an insider. The excerpt lists multiple disposition dates in Q1 2026 and specific lots attributed to Michael Smith, including 24,774 shares on 02/24/2026 and earlier smaller lots in January and February.
Insmed Inc: The Vanguard Group filed an amendment to its Schedule 13G/A reporting beneficial ownership of 0 shares of Common Stock.
The filing explains an internal realignment effective January 12, 2026, that disaggregated certain Vanguard subsidiaries for SEC reporting; the report shows no sole or shared voting or dispositive power over Insmed shares.
Insmed Incorporated reported positive topline results from its Phase 3b ENCORE study of ARIKAYCE in patients with newly diagnosed MAC lung infection not previously treated with antibiotics. ARIKAYCE plus multidrug therapy improved Respiratory Symptom Score at Month 13 by 17.77 points versus 14.66 with placebo, a 3.11‑point advantage (p=0.0299), and achieved culture conversion by Month 6 in 87.8% of patients versus 57.0% with placebo. By Month 15, a significantly greater proportion of ARIKAYCE patients maintained durable culture conversion, and overall study completion exceeded 90% in both arms, with a safety profile consistent with known risks such as dysphonia, cough and bronchospasm. These results fulfill the U.S. FDA post‑marketing requirement, and Insmed plans a supplemental NDA in the second half of 2026 to seek U.S. label expansion and conversion of ARIKAYCE’s existing refractory indication to traditional approval, as well as a parallel submission to Japan’s PMDA.
INSMED Inc Chair and CEO William Lewis exercised stock options and sold shares in a planned transaction. On 2026-03-19, he exercised options for 10,699 shares of common stock at exercise prices of $30.46 and $17.16 per share, converting them into common shares.
That same day, he sold 10,699 shares of common stock in open-market trades at weighted average prices ranging from about $141.80 to $144.72, under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. After these transactions, he directly holds 301,185 shares, plus 233,924 shares held indirectly through the Katie Procter Dynasty Trust.
William Lewis filed a Form 144 reporting proposed sales of issuer common stock. The filing lists multiple Stock Plan Activity entries with proposed dispositions dated 03/19/2026 and earlier trade dates. Examples shown include proposed sales of 10,699 shares on 03/05/2026 and 10,699 shares on 02/19/2026. The filing lists repeated transactions under the same reporting address and identifies the market as NASDAQ.